IBA Molecular awarded 3-year group purchasing agreement with Premier, Inc.
Dulles, Virginia May 22, 2014 – IBA Molecular North America, Inc. (IBA Molecular) announced the signing of a 3-year group purchasing agreement with Premier, Inc. (Premier), a leading health care improvement company, to offer PET radiopharmaceuticals, including 18F-Fluorodeoxyglucose (FDG), a diagnostic radiotracer used in oncology, neurology and cardiology, to Premier member imaging centers across the country. Premier provides integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services to a broad range of healthcare providers in the United States.
This agreement will continue IBA Molecular’s outstanding service to Premier member sites. In addition to providing radioisotopes to these advanced imaging programs IBA Molecular will offer its wide range of PET education and support programs, unique in the industry. The company’s commitment to improved quality in molecular imaging is reflected in the educational resources and programs which it has developed. Creating customized action plans in education, service enhancement and outreach, IBA Molecular assists imaging programs in increasing their impact and value in the medical community. The ultimate goal is to help ensure that each patient receives the correct diagnosis and effective treatment at the appropriate time.
Lee Karras, President of IBA Molecular, noted “We are excited about continuing our outstanding relationship with Premier, working with them in providing exceptional value and support to member sites, and helping Premier member organizations in their efforts to deliver effective diagnostic services to the patients they serve.”
This agreement, which will extend IBA Molecular’s current service to Premier member sites, will commence on July 1, 2014, and will be in place for a period of three years.
About IBA Molecular North America, Inc.
IBA Molecular North America, Inc. is part of IBA Molecular, a global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. Founded in 1986, IBA Molecular, with North American headquarters in Dulles, Virginia, is jointly owned by SK Capital Partners and Ion Beam Applications S.A. The company is a leading manufacturer and distributor of PET agents in North America, and PET and SPECT agents in Europe and Asia, with a network of 49 sites worldwide.
About Premier, Inc.
Premier, Inc. is a leading healthcare improvement company, uniting an alliance of more than 2,900 U.S. hospitals and nearly 100,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news/investor sites on www.premierinc.com for more information about the company. We are also on Facebook, LinkedIn, YouTube, Instagram and Foursquare.